Lymphoscintigraphy and sentinel nodes

Journal of Nuclear Medicine

Volumn 56, Issue 6, 2015, Pages 901-907

  Moncayo, Valeria M ^a   Aarsvold, John N ^a,b   Alazraki, Naomi P ^a,b  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Lymphoscintigraphy; Melanoma; Sentinel lymph node

Indexed keywords

DEXTRAN; LIDOCAINE; PERTECHNETIC ACID TC 99M; PRILOCAINE; TECHNETIUM SULFUR COLLOID TC 99M; TILMANOCEPT TC 99M; TECHNETIUM;

ARTICLE; BREAST CANCER; CLINICAL PROTOCOL; DISEASE FREE SURVIVAL; HEAD AND NECK CANCER; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MELANOMA; MORBIDITY; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE; SYSTEMATIC REVIEW; VALIDATION PROCESS; ADULT; AGED; BIOPSY; CANCER STAGING; CHEMISTRY; FEMALE; LABORATORY DIAGNOSIS; LYMPH NODE; MALE; METASTASIS; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; SCINTISCANNING; SKIN TUMOR; TUMOR RECURRENCE;

ADULT; AGED; BIOPSY; DISEASE-FREE SURVIVAL; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHOSCINTIGRAPHY; MALE; MELANOMA; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TECHNETIUM;

EID: 84930369360     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.141432     Document Type: Article

References (67)

1. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes: analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg. 1991;214:491-499.
2. Alex JC, Krag DN. Gamma-probe guided localization of lymph nodes. Surg Oncol. 1993;2:137-143.
3. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-399.
4. Aarsvold JN, Alazraki NP. Update on detection of sentinel lymph nodes in patients with breast cancer. Semin Nucl Med. 2005;35:116-128.
5. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer. 1977;39:456-466.
6. Sondak VK, Wong SL, Gershenwald JE, Thompson JF. Evidence-based clinical practice guidelines on the use of sentinel lymph node biopsy in melanoma. Am Soc Clin Oncol Educ Book. 2013.
7. Krynyckyi BR, Kim CK, Goyenechea MR, Chan PT, Zhang ZY, Machac J. Clinical breast lymphoscintigraphy: optimal techniques for performing studies, image atlas, and analysis of images. Radiographics. 2004;24:121-145.
8. Lymphoseek (technetium Tc 99m tilmanocept) [package insert]. Dublin, OH: Navidea Pharmaceuticals; 2013.
9. Wallace AM, Hoh CK, Vera DR, Darrah DD, Schulteis G. Lymphoseek: a molecular radiopharmaceutical for sentinel node detection. Ann Surg Oncol. 2003;10:531-538.
10. Giammarile F, Alazraki N, Aarsvold JN, et al. The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. Eur J Nucl Med Mol Imaging. 2013;40:1932-1947.
11. Johnson CB, Boneti C, Korourian S, Adkins L, Klimberg VS. Intraoperative injection of subareolar or dermal radioisotope results in predictable identification of sentinel lymph nodes in breast cancer. Ann Surg. 2011;254:612-618.
12. Lin KM, Patel TH, Ray A, et al. Intradermal radioisotope is superior to peritumoral blue dye or radioisotope in identifying breast cancer sentinel nodes. J Am Coll Surg. 2004;199:561-566.
13. Sanli Y, Berberoglu K, Turkmen C, et al. The value of combined peritumoral and subdermal injection techniques for lymphoscintigraphy in detection of sentinel lymph node in breast cancer. Clin Nucl Med. 2006;31:690-693.
14. Rodier JF, Velten M, Wilt M, et al. Prospective multicentric randomized study comparing periareolar and peritumoral injection of radiotracer and blue dye for the detection of sentinel lymph node in breast sparing procedures: FRANSENODE trial. J Clin Oncol. 2007;25:3664-3669.
15. Moncayo VM, Aarsvold JN, Grant SF, Bartley SC, Alazraki NP. Status of sentinel lymph node for breast cancer. Semin Nucl Med. 2013;43:281-293.
16. Uren RF, Howman-Giles R, Thompson JF. Patterns of lymphatic drainage from the skin in patients with melanoma. J Nucl Med. 2003;44:570-582.
17. van der Ploeg IM, Valdes Olmos RA, Nieweg OE, Rutgers EJ, Kroon BB, Hoefnagel CA. The additional value of SPECT/CT in lymphatic mapping in breast cancer and melanoma. J Nucl Med. 2007;48:1756-1760.
18. Mar MV, Miller SA, Kim EE, Macapinlac HA. Evaluation and localization of lymphatic drainage and sentinel lymph nodes in patients with head and neck melanomas by hybrid SPECT/CT lymphoscintigraphic imaging. J Nucl Med Technol. 2007;35:10-16.
19. Uren RF, Howman-Giles R, Chung DK, et al. SPECT/CT scans allow precise anatomical location of sentinel lymph nodes in breast cancer and redefine lymphatic drainage from the breast to the axilla. Breast. 2012;21:480-486.
20. van der Ploeg IM, Valdes Olmos R, Kroon B, Nieweg O. The hybrid SPECT/CT as an additional lymphatic mapping tool in patients with breast cancer. World J Surg. 2008;32:1930-1934.
21. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in earlystage breast cancer. J Clin Oncol. 2005;23:7703-7720.
22. van der Ploeg IM, Nieweg OE, van Rijk MC, Valdes Olmos RA, Kroon BB. Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol. 2008;34:1277-1284.
23. Tafra L, McMasters KM, Whitworth P, Edwards MJ. Credentialing issues with sentinel lymph node staging for breast cancer. Am J Surg. 2000;180:268-273.
24. Intra M, Rotmensz N, Veronesi P, et al. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: The experience of the European Institute of Oncology on 854 patients in 10 years. Ann Surg. 2008;247:315-319.
25. Camp R, Feezor R, Kasraeian A, et al. Sentinel lymph node biopsy for ductal carcinoma in situ: an evolving approach at the University of Florida. Breast J. 2005;11:394-397.
26. Pechlivanides G, Vassilaros D, Tsimpanis A, Apostolopoulou A, Vasilaros S. Sentinel node biopsy for breast cancer patients: issues for discussion and our practice. Patholog Res Int. 2011:109712.
27. Ansari B, Boughey JC. Sentinel lymph node surgery in uncommon clinical circumstances. Surg Oncol Clin N Am. 2010;19:539-553.
28. Hindié E, Groheux D, Brenot-Rossi I, Rubello D, Moretti JL, Espie M. The sentinel node procedure in breast cancer: nuclear medicine as the starting point. J Nucl Med. 2011;52:405-414.
29. Kang E, Chung IY, Han SA, et al. Feasibility of sentinel lymph node biopsy in breast cancer patients with initial axillary lymph node metastasis after primary systemic therapy. J. Breast Cancer. 2011;14:147-152.
30. Kelly AM, Dwamena B, Cronin P, Carlos RC. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis. Acad Radiol. 2009;16:551-563.
31. van Deurzen CH, Vriens BE, Tjan-Heijnen VC, et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer. 2009;45:3124-3130.
32. Xing Y, Foy M, Cox D, Kuerer H, Hunt K, Cormier J. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006;93:539-546.
33. Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455-1461.
34. Ashikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102:111-118.
35. Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: The American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:426-432.
36. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically nodenegative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11:927-933.
37. Veronesi U, Viale G, Paganelli G, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251:595-600.
38. Zavagno G, De Salvo GL, Scalco G, et al. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg. 2008;247:207-213.
39. Gentilini O, Veronesi P, Botteri E, et al. Sentinel lymph node biopsy in multicentric breast cancer: five-year results in a large series from a single institution. Ann Surg Oncol. 2011;18:2879-2884.
40. Del Bianco P, Zavagno G, Burelli P, et al. Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomised clinical trial. Eur J Surg Oncol. 2008;34:508-513.
41. Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operative arm morbidity and quality of life: results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat. 2006;95:279-293.
42. Fougo JL, Dinis-Ribeiro M, Araujo C, et al. Impact of lymphadenectomy on axillary recurrence and morbidity of the upper limb in breast cancer patients with negative sentinel node: a prospective randomised study. Cir Esp. 2011;89: 307-316.
43. Goyal A, Newcombe RG, Chhabra A, Mansel RE. Morbidity in breast cancer patients with sentinel node metastases undergoing delayed axillary lymph node dissection (ALND) compared with immediate ALND. Ann Surg Oncol. 2008;15:262-267.
44. Helms G, Kuhn T, Moser L, Remmel E, Kreienberg R. Shoulder-arm morbidity in patients with sentinel node biopsy and complete axillary dissection: data from a prospective randomised trial. Eur J Surg Oncol. 2009;35:696-701.
45. Purushotham AD, Upponi S, Klevesath MB, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005;23:4312-4321.
46. Chakera AH, Hesse B, Burak Z, et al. EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging. 2009;36:1713-1742.
47. NCCN guidelines for treatment of cancer by site: penile cancer. National Comprehensive Cancer Center website. http://www.nccn.org/professionals/physician-gls/ f-guidelines.asp#site. Accessed April 27, 2015.
48. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206.
49. McMasters KM, Wong SL, Edwards MJ, et al. Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery. 2001;130:151-156.
50. Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol. 2012;30:2912-2918.
51. Karakousis GC, Gimotty PA, Czerniecki BJ, et al. Regional nodal metastatic disease is the strongest predictor of survival in patients with thin vertical growth phase melanomas: a case for SLN staging biopsy in these patients. Ann Surg Oncol. 2007;14:1596-1603.
52. Karakousis GC, Gimotty PA, Botbyl JD, et al. Predictors of regional nodal disease in patients with thin melanomas. Ann Surg Oncol. 2006;13:533-541.
53. Bedrosian I, Faries MB, Guerry DT, et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (, or 5 1 mm) with vertical growth phase. Ann Surg Oncol. 2000;7:262-267.
54. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599-609.
55. Pasquali S, Spillane A. Contemporary controversies and perspectives in the staging and treatment of patients with lymph node metastasis from melanoma, especially with regards positive sentinel lymph node biopsy. Cancer Treat Rev. 2014;40:893-899.
56. Pasquali S, Mocellin S, Campana LG, et al. Early (sentinel lymph node biopsyguided) versus delayed lymphadenectomy in melanoma patients with lymph node metastases: personal experience and literature meta-analysis. Cancer. 2010;116:1201-1209.
57. Morton DL. Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma. Clin Exp Metastasis. 2012;29:699-706.
58. McNeil C. Does every melanoma patient with a positive sentinel node need more lymph nodes removed? The ASCO Post website. http://www.ascopost.com/ issues/may-1,-2013/higher-her2-expression-linked-to-best-results-with-t-dm1-inpatients-with.aspx. Published May 1, 2013. Accessed April 27, 2015.
59. Alex JC, Sasaki CT, Krag DN, Wenig B, Pyle PB. Sentinel lymph node radiolocalization in head and neck squamous cell carcinoma. Laryngoscope. 2000; 110:198-203.
60. Radkani P, Mesko TW, Paramo JC. Validation of the sentinel lymph node biopsy technique in head and neck cancers of the oral cavity. Am Surg. 2013;79:1295-1297.
61. Alkureishi LW, Burak Z, Alvarez JA, et al. Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2009;36:1915-1936.
62. Stoeckli SJ, Steinert H, Pfaltz M, Schmid S. Sentinel lymph node evaluation in squamous cell carcinoma of the head and neck. Otolaryngol Head Neck Surg. 2001;125:221-226.
63. Ross GL, Soutar DS, Gordon MacDonald D, et al. Sentinel node biopsy in head and neck cancer: preliminary results of a multicenter trial. Ann Surg Oncol. 2004;11:690-696.
64. Bilde A, Von Buchwald C, Mortensen J, et al. The role of SPECT-CT in the lymphoscintigraphic identification of sentinel nodes in patients with oral cancer. Acta Otolaryngol. 2006;126:1096-1103.
65. Wagner A, Schicho K, Glaser C, et al. SPECT-CT for topographic mapping of sentinel lymph nodes prior to gamma probe-guided biopsy in head and neck squamous cell carcinoma. J Craniomaxillofac Surg. 2004;32:343-349.
66. Schaafsma BE, Mieog JS, Hutteman M, et al. The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. J Surg Oncol. 2011;104:323-332.
67. van der Vorst JR, Schaafsma BE, Verbeek FP, et al. Near-infrared fluorescence sentinel lymph node mapping of the oral cavity in head and neck cancer patients. Oral Oncol. 2013;49:15-19.